Saturday Edition
Stay updated with Archyde – your source for breaking news, global headlines, economy, entertainment, health, technology, and sports. Fresh stories daily.
Clear Street Research has upgraded LB Pharmaceuticals Inc. (NASDAQ: LBRX) to a Buy rating with a $45 price target, citing “breakthrough potential” in its lead drug, LBRX-101, a novel small-molecule ... Read More
Continuous Coverage
In the neon-lit backstreets of Tokyo’s Akihabara district, where vending machines dispense more than just snacks, a new…
Adjuvant pembrolizumab has emerged as a significant consideration for patients with high-risk renal cell carcinoma (RCC) following nephrectomy.…
Roland-Garros 2026 crowned Carlos Alcaraz as the first Spaniard to back-to-back defend a Grand Slam title, while Iga…
Sarah Ferguson’s carefully cultivated post-royalty brand—rooted in media appearances, lifestyle partnerships, and a decades-long reinvention—faces an existential threat…
Carrefour (EPA: CARR) is restructuring its Hasselt store, reducing its size by 50% and integrating new retail formats,…
As of late Tuesday, Israeli Defense Forces (IDF) operations in southern Lebanon reportedly crossed the UN-mandated “Blue Line”—the…
Global Affairs
As of late May 2026, Asia is undergoing a profound transformation in its tourism and economic landscape, shifting…
Markets And Money
The South Korean equity market, led by the Korea Composite Stock Price Index (KOSPI), has realized an 80%…
Digital Culture
007 First Light has officially arrived, earning critical acclaim as the most significant James Bond title since the…
Science And Wellbeing
Cervical cancer remains the fourth most deadly cancer among women globally, but HPV vaccination and regular screening—when combined—reduce…
Screen And Sound
After five years in exile, Vicky Zhao’s viral photos reveal a calculated escape from China’s entertainment purgatory, leveraging…
Fixtures And Form
The 2026 World Championship Knockout Stage: Elite Tactical Shifts and High-Stakes Parity The 2026 IIHF World Championship group…
